Alaunos Therapeutics
TCRT
128 hedge funds and large institutions have $237M invested in Alaunos Therapeutics in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 12 closing their positions.
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 31
5% more funds holding
Funds holding: 122 → 128 (+6)
0% less ownership
Funds ownership: 0.27% → 0.27% (-0%)
33% less capital invested
Capital invested by funds: $356M → $237M (-$119M)
55% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $6.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$6.64M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.46M |
| 3 |
BlackRock
New York
|
+$1.34M |
| 4 |
Citigroup
New York
|
+$1.3M |
| 5 |
MVP
Miller Value Partners
Sarasota,
Florida
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.8M |
| 2 |
Millennium Management
New York
|
-$843K |
| 3 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$437K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$435K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$406K |
TCRT Hedge Fund Activity: Q4 2017 in Review
128 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2017, worth a combined $237M — down 33% from $356M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TCRT positions and 12 closed out — a net gain of 7 holders — while 37 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $6.64M. The largest seller was Susquehanna International Group, cutting an estimated $16.8M.
- 128 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2017, up from 122 in Q3 2017.
- Funds reported $237M of Alaunos Therapeutics stock for Q4 2017, down 33% quarter-over-quarter.
- 19 funds opened new Alaunos Therapeutics positions in Q4 2017 and 12 closed out, a net change of +7 holders.
- The largest Alaunos Therapeutics buyer in Q4 2017 was State Street, an estimated $6.64M added.
- The largest Alaunos Therapeutics seller in Q4 2017 was Susquehanna International Group, an estimated $16.8M sold.
Based on aggregated 13F filings for Q4 2017.